Literature DB >> 21048008

Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Sarah W Satola1, Monica M Farley, Karen F Anderson, Jean B Patel.   

Abstract

Staphylococcus aureus clinical isolates with vancomycin MICs of 2 μg/ml have been associated with vancomycin therapeutic failure and the heteroresistant vancomycin-intermediate S. aureus (hVISA) phenotype. A population analysis profile (PAP) with an area under the curve (AUC) ratio of ≥ 0.9 for the AUC of the clinical isolate versus the AUC for hVISA strain Mu3 is most often used for determining hVISA, but it is time-consuming and labor-intensive. A collection of 140 MRSA blood isolates with vancomycin MICs of 2 μg/ml by reference broth microdilution and screened for hVISA using PAP-AUC (21/140 [15%] hVISA) were tested by additional methods to detect hVISA. The methods included (i) Etest macromethod using vancomycin and teicoplanin test strips, brain heart infusion (BHI) agar, and a 2.0 McFarland inoculum; (ii) Etest glycopeptide resistance detection (GRD) using vancomycin-teicoplanin double-sided gradient test strips on Mueller-Hinton agar (MHA) with 5% sheep blood and a 0.5 McFarland inoculum; and (iii) BHI screen agar plates containing 4 μg/ml vancomycin and 16 g/liter casein using 0.5 and 2.0 McFarland inocula. Each method was evaluated using PAP-AUC as the reference method. The sensitivity of each method for detecting hVISA was higher when the results were read at 48 h. The Etest macromethod was 57% sensitive and 96% specific, Etest GRD was 57% sensitive and 97% specific, and BHI screen agar was 90% sensitive and 95% specific with a 0.5 McFarland inoculum and 100% sensitive and 68% specific with a 2.0 McFarland inoculum. BHI screen agar with 4 μg/ml vancomycin and casein and a 0.5 McFarland inoculum had the best sensitivity and specificity combination, was easy to perform, and may be useful for clinical detection of hVISA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21048008      PMCID: PMC3020420          DOI: 10.1128/JCM.01128-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  41 in total

1.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.

Authors:  George Sakoulas; Robert C Moellering; George M Eliopoulos
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

Review 3.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

4.  The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.

Authors:  K Hiramatsu
Journal:  Am J Med       Date:  1998-05-29       Impact factor: 4.965

5.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

6.  Low-level teicoplanin resistance and heteroresistance to vancomycin.

Authors:  K Sieradzki; P Villari; A Tomasz
Journal:  Ann Intern Med       Date:  1998-02-01       Impact factor: 25.391

7.  A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.

Authors:  Fabien Garnier; Delphine Chainier; Timothy Walsh; Asa Karlsson; Anne Bolmström; Carole Grelaud; Marcelle Mounier; François Denis; Marie-Cécile Ploy
Journal:  J Antimicrob Chemother       Date:  2005-11-14       Impact factor: 5.790

8.  Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

Authors:  J Ariza; M Pujol; J Cabo; C Peña; N Fernández; J Liñares; J Ayats; F Gudiol
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

9.  Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.

Authors:  Darego O Maclayton; Katie J Suda; Krista A Coval; Cynthia B York; Kevin W Garey
Journal:  Clin Ther       Date:  2006-08       Impact factor: 3.393

10.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

View more
  42 in total

1.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.

Authors:  Riad Khatib; Kathleen Riederer; Mamta Sharma; Stephen Shemes; Sugantha P Iyer; Susan Szpunar
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

3.  Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.

Authors:  Sheila Adams-Sapper; Shantell Nolen; Grace Fox Donzelli; Mallika Lal; Kunihiko Chen; Livia Helena Justo da Silva; Beatriz M Moreira; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

4.  Using genomics to standardize population analysis profile-area under the curve ratio for vancomycin-intermediate Staphylococcus aureus.

Authors:  Timothy D Read; Sarah W Satola
Journal:  J Clin Microbiol       Date:  2014-07-23       Impact factor: 5.948

5.  Heterogeneous glycopeptide intermediate Staphylococcus epidermidis isolated from prosthetic joint infections.

Authors:  S Tevell; C Claesson; B Hellmark; B Söderquist; Å Nilsdotter-Augustinsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-14       Impact factor: 3.267

6.  Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin.

Authors:  Kerry J Welsh; Kimberly A Skrobarcek; April N Abbott; Cole T Lewis; Mark C Kruzel; Evan M Lewis; Jeanelle M Gardiner; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

7.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

8.  Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia.

Authors:  Jennifer H Han; Kara B Mascitti; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

9.  First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.

Authors:  Doo Ryeon Chung; Jin Yang Baek; Hyun Ah Kim; Min Hee Lim; So Hyun Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

10.  The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Jennifer H Han; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  J Infect       Date:  2012-09-06       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.